Lyra Therapeutics Inc (LYRA)

$1.32 -0.02 (-1.49%)
Market Cap 2.34M
Revenue (ttm) 1.53M
Net Income (ttm) -93.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,107.19%
Debt to Equity Ratio 0.00
Volume 3,200
Avg Vol 89,948
Day's Range N/A - N/A
Shares Out 1.78M
Stochastic %K 70%
Beta 0.00
Analysts Hold
Price Target $16.00

Company Profile

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 393 4600
Address:
480 Arsenal Way, Watertown, United States
luminouslumens
luminouslumens Mar. 15 at 6:20 PM
$ADV $EONR $TWAV $CYN $LYRA Multi-day runner scan going into Monday.
0 · Reply
ChetdaJet
ChetdaJet Mar. 6 at 5:47 AM
$LYRA is this company still in business??
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 3:25 PM
$LYRA RSI: 36.24, MACD: -0.2954 Vol: 0.25, MA20: 1.45, MA50: 2.23 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockScanners
StockScanners Mar. 3 at 6:40 AM
$LYRA keep watch if this holds above .99
0 · Reply
Golibajje
Golibajje Mar. 2 at 3:17 PM
$LYRA CEO is an evil!! Its all well planned for taking it to ground! Sabby took 9.90% long position on Jan 20 to short heavily.. I m sure mgmt is involved with them!
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 2 at 2:52 PM
$LYRA No deal on lease. = bankruptcy and delisting next
0 · Reply
Golibajje
Golibajje Feb. 26 at 8:14 PM
$LYRA Well!! Sabby is a cancer to stocks! Not seen any small cap company survived from their brutal shorting! Looks like delisting news leaked to them!
1 · Reply
revuelto
revuelto Feb. 26 at 7:18 PM
$LYRA whatever the outcome, it’s imminent👍
0 · Reply
aafetygod
aafetygod Feb. 26 at 12:23 PM
$LYRA 3-4 or delist
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 3:22 PM
$LYRA Current Stock Price: $1.45
0 · Reply
Latest News on LYRA
Lyra Therapeutics Provides Corporate Update

Jan 12, 2026, 7:00 AM EST - 2 months ago

Lyra Therapeutics Provides Corporate Update

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 4 months ago

Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Oct 6, 2025, 7:00 AM EDT - 5 months ago

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 27, 2025, 8:00 AM EDT - 9 months ago

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Jun 16, 2025, 4:14 PM EDT - 9 months ago

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Jun 2, 2025, 8:29 AM EDT - 10 months ago

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Jun 2, 2025, 7:00 AM EDT - 10 months ago

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

May 7, 2025, 7:00 AM EDT - 11 months ago

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:01 PM EDT - 11 months ago

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Sep 27, 2024, 7:00 AM EDT - 1 year ago

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

May 21, 2024, 9:14 AM EDT - 1 year ago

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

May 6, 2024, 7:59 AM EDT - 2 years ago

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:04 PM EDT - 2 years ago

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

3 'Buy-Rated' Biotech Stocks Under $10

Apr 28, 2024, 4:39 AM EDT - 2 years ago

3 'Buy-Rated' Biotech Stocks Under $10

ADMA GERN

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 26, 2024, 4:51 PM EDT - 2 years ago

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 1, 2024, 4:01 PM EST - 2 years ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 4:01 PM EST - 2 years ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Nov 7, 2023, 7:00 AM EST - 2 years ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Lyra Therapeutics: Hold For Phase 3 Topline

Oct 10, 2023, 10:56 AM EDT - 2 years ago

Lyra Therapeutics: Hold For Phase 3 Topline

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Oct 9, 2023, 1:20 AM EDT - 2 years ago

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jul 13, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 2, 2023, 7:30 AM EDT - 3 years ago

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

Jun 1, 2023, 7:29 AM EDT - 3 years ago

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

Lyra Therapeutics Announces $50.0 Million Private Placement

May 26, 2023, 7:57 AM EDT - 3 years ago

Lyra Therapeutics Announces $50.0 Million Private Placement

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

May 9, 2023, 4:01 PM EDT - 3 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Apr 25, 2023, 7:59 AM EDT - 3 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Apr 5, 2023, 9:04 AM EDT - 3 years ago

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 29, 2023, 4:06 PM EDT - 3 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 27, 2023, 7:59 AM EST - 3 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Feb 6, 2023, 7:56 AM EST - 3 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 4:01 PM EST - 3 years ago

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 10, 2022, 8:00 AM EDT - 3 years ago

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 29, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 9, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Jul 5, 2022, 7:00 AM EDT - 4 years ago

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

luminouslumens
luminouslumens Mar. 15 at 6:20 PM
$ADV $EONR $TWAV $CYN $LYRA Multi-day runner scan going into Monday.
0 · Reply
ChetdaJet
ChetdaJet Mar. 6 at 5:47 AM
$LYRA is this company still in business??
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 3:25 PM
$LYRA RSI: 36.24, MACD: -0.2954 Vol: 0.25, MA20: 1.45, MA50: 2.23 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockScanners
StockScanners Mar. 3 at 6:40 AM
$LYRA keep watch if this holds above .99
0 · Reply
Golibajje
Golibajje Mar. 2 at 3:17 PM
$LYRA CEO is an evil!! Its all well planned for taking it to ground! Sabby took 9.90% long position on Jan 20 to short heavily.. I m sure mgmt is involved with them!
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 2 at 2:52 PM
$LYRA No deal on lease. = bankruptcy and delisting next
0 · Reply
Golibajje
Golibajje Feb. 26 at 8:14 PM
$LYRA Well!! Sabby is a cancer to stocks! Not seen any small cap company survived from their brutal shorting! Looks like delisting news leaked to them!
1 · Reply
revuelto
revuelto Feb. 26 at 7:18 PM
$LYRA whatever the outcome, it’s imminent👍
0 · Reply
aafetygod
aafetygod Feb. 26 at 12:23 PM
$LYRA 3-4 or delist
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 3:22 PM
$LYRA Current Stock Price: $1.45
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 18 at 4:03 PM
$QNCX it is $LYRA 's turn
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 18 at 2:39 PM
$SNSE $LYRA next? Major risks are delisting + cash runway into Q3... But $2.5M market cap is too low if they manage to make ANY deal
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Feb. 18 at 2:27 PM
$LYRA Buy now or wait for delisting? I hate the short cash runwau though. Management has failed
1 · Reply
FloatWolf
FloatWolf Feb. 17 at 9:34 AM
$LYRA Pre-revenue biotech; early-stage
0 · Reply
Raymondsuper
Raymondsuper Feb. 14 at 1:45 AM
$LYRA not looking good no product no revenue I don’t k how they survive
0 · Reply
Golibajje
Golibajje Feb. 13 at 2:34 PM
$LYRA There is a reason why Sabby entered with 9.90% long position to short right after that corporate update! and it’s definitely not for good reason! Reminds me of cash rich $EFTR which was taken to 0 by the mgmt by spending all the cash! $LYRA mgmt seems to have similar intention!
1 · Reply
peepthestamp
peepthestamp Feb. 13 at 1:03 PM
$LYRA -Buy Lows
0 · Reply
Golibajje
Golibajje Feb. 11 at 10:59 PM
$LYRA Still wondering what is fraudster Sabby’s evil intention to short this? 1.7m float trading at $1.36!
0 · Reply
revuelto
revuelto Feb. 10 at 5:50 PM
$LYRA at a minimum, you should receive $1.5 if everything else falls apart, I think…worth taking a small position 😀
0 · Reply
Golibajje
Golibajje Feb. 9 at 4:55 PM
$LYRA the time Sabby took the long position to short last month, this is pretty much over! This company was good initially backed by Perceptive Advisors.. however, greedy mgmt kept spending money with less progress!
0 · Reply
revuelto
revuelto Feb. 8 at 11:22 AM
$LYRA reading between the lines, and I’m doing quite a bit of that here, buyers at these levels should be well rewarded, or… the “or” scenario feels far less likely to me…the risk/reward on this one is very real✌️
0 · Reply
HatimIsHere
HatimIsHere Feb. 7 at 9:25 PM
$LYRA On February 2, 2026, Lyra Therapeutics, Inc. was notified by Nasdaq of its intention to delist the company’s common stock due to non-compliance with listing standards and significant operational changes, including workforce reductions and the suspension of development of its lead product.
0 · Reply